Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. The most common is type 2 diabetes, usually in adults, which occurs when the body becomes resistant to insulin or doesn't make enough insulin. In the past three decades the prevalence of type 2 diabetes has risen dramatically in countries of all income levels. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin by itself. For people living with diabetes, access to affordable treatment, including insulin, is critical to their survival. There is a globally agreed target to halt the rise in diabetes and obesity by 2025.
About 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
Diabetes Actual seeks to restore metabolic wellness through the use of proven therapies that reverse the ravages of diabetes by restoring insulin sensitivity. This is made possible through a partnership with the US-based company, WellCell Global, as we deploy their FDA-approved, life-saving technology throughout the world.
With over 7,000 patients treated across 45 US clinics and 5 international treatment centers, their patented technology promotes cell health and organ revitalization, using a safe method that has evolved over the last 70 years of scientific progress. By focusing on the body as a whole, Diabetes Actual can increase overall health by restoring metabolic wellness. The key is regaining insulin sensitivity and is based on restoring the normal rhythmic release of insulin.